Navigating Treatment Decisions for EGFR-Mutated NSCLC With High-Risk Features

Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, examine treatment considerations for patients with high-risk EGFR-mutated NSCLC, including those with CNS metastases or co-occurring genomic alterations. Neal reviews how disease burden and aggressive clinical features may influence the choice of combination therapy. Goldberg highlights the need for individualized approaches that balance response depth with tolerability in vulnerable populations.